The archive · Bio & Materials · Strategic decision · 2019–2025
54gene's African-genomics bet: $45M raised, 100,000-sample biobank, then 2023 wind-down
54gene bet African DNA would power global drug discovery; a $45M war chest and 100,000-sample biobank ended in July 2023 wind-down and a frozen asset sale.
54gene
What the business is
54gene was a Lagos-based genomics company that built a biobank of African DNA samples and ran sequencing and diagnostics services, aiming to supply pharma with data from the world's most genetically diverse continent.
Starting capital：US$45M+ across three rounds ($4.5M seed in 2019, $15M Series A led by Adjuvant in 2020, $25M Series B led by Cathay AfricInvest in 2021)
How it started
Founded in early 2019 in Lagos by Dr. Abasi Ene-Obong, a geneticist and former pharma consultant, 54gene set out to build the continent's largest biobank. It joined Y Combinator and Google for Startups, raised a then-record $4.5M seed for Nigerian healthtech, and closed a $15M Series A with Adjuvant Capital in April 2020.
What happened
A $25M Series B in September 2021 funded a whole-genome sequencing lab and a diagnostics arm, Seven River Labs. During COVID 54gene scaled Nigeria's daily testing from about 100 to over 1,000 samples and booked $20M+ in revenue; its biobank reached 100,000 Nigerians across 300 ethnic groups and its valuation peaked around $170M. When COVID demand collapsed, a planned $100M Series C failed, 95 staff were laid off, and the CEO changed twice within a year.
How it ended up
In July 2023 54gene began winding down — "could not continue to operate financially," said then-CEO Ron Chiarello — and by September its website was gone. In August 2025 a Lagos Federal High Court blocked the sale of its assets, including biodata of 100,000 Nigerians priced at $3M, while founder Ene-Obong alleged the lead investors engineered the collapse; the case was pending.
Background
54gene was founded in Lagos in early 2019 by geneticist Dr. Abasi Ene-Obong on a sharp observation: Africa is the most genetically diverse continent, yet under 3% of the genetic material used in global pharmaceutical research comes from it. The bet was that this data gap itself was a business — build Africa's largest biobank, then sell researchers and drug companies access to it.
The company moved fast. It joined Y Combinator, raised a then-record $4.5M seed for Nigerian healthtech, then $15M from Adjuvant Capital and $25M from Cathay AfricInvest, building a whole-genome sequencing lab and a diagnostics arm. During the pandemic it helped scale Nigeria's COVID testing from roughly 100 to over 1,000 daily samples, booking $20M+ in revenue, while assembling a biobank of 100,000 Nigerians across 300 ethnic groups at a peak valuation of about $170M.
The collapse was just as fast. When COVID demand disappeared, a $100M Series C failed, 95 staff were laid off, and the company cycled through three CEOs in a year. In July 2023 it began winding down — "could not continue to operate financially," said then-CEO Ron Chiarello. In August 2025 a Lagos court blocked the sale of its assets, including biodata of 100,000 Nigerians priced at $3M, as the founder and lead investors fought over who had destroyed the company.
What has to be true
- Africa's genetic diversity was genuinely underrepresented in research, so the gap 54gene attacked was real and measurable.
- COVID diagnostics brought revenue and national relevance, but that revenue was cyclical — not a recurring data business — and masked weak product-market fit.
- Sequencing equipment and biobanking are capital-intensive, so when post-COVID revenue fell and the next round failed, the fixed costs were untenable.
- Founder-investor conflict — two CEO changes in a year and a reported valuation cut from $170M to $50M — destroyed the confidence needed to raise or sell.
What can be applied
A data asset is worth only what a customer will pay today: 54gene proved demand for African genomics, but the value stayed a promise once COVID testing revenue vanished.
Aftermath
As of September 2025 54gene was defunct and its assets were frozen in litigation. Winding down began in July 2023; by September its website was gone. In August 2025 a Lagos Federal High Court injunction blocked the sale of its biobank — biodata of 100,000 Nigerians priced at $3M — in proceedings brought by founder Abasi Ene-Obong, who alleged Cathay AfricInvest and Adjuvant engineered the collapse of a company once valued near $170M. The investors said they acted in the company's best interests; the case awaited judgment, and Ene-Obong had moved on to a new venture, Syndicate Bio.
Sources
- New Nigerian Biobank Advances Africa's Genomic Revolution
- Exclusif : Après avoir levé 45 millions de dollars en deux ans, 54Gene ferme ses portes.
- 54Gene's $45m funding couldn't prevent biotech startup collapse
- Nigerian court blocks sale of 54gene's assets
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card